< PreviousSCIENTIFIC PROGRAMME110 S062311:30Involving patients in research for better outcomes Judith Strawbridge (Dublin, Ireland) Co-organised with: ESCMID Study Group for Clostridioides difficile (ESGCD) CM SY15211:00 - 12:00Hall I 1-Hour Symposium Antimicrobial resistance and COVID-19: increase or decrease? ChairsDominique Monnet (Stockholm, Sweden) Saskia Nahrgang (Copenhagen, Denmark) S062411:00Antimicrobial resistance, antimicrobial use and COVID-19: an intensive care perspective Jose Artur Paiva (Porto, Portugal) S062511:30Antimicrobial resistance, antimicrobial use and COVID-19: a cross-healthcare perspective Alison Helen Holmes (London, United Kingdom) Co-organised with: European Centre for Disease Prevention and Control (ECDC) OS15311:00 - 12:00Hall F 1-Hour Oral Session Novel observations in protective host responses to infection ChairsMichael G. Ison (Chicago, United States) Nina Khanna (Basel, Switzerland) O0626A D-glutamate auxotrophic Pseudomonas aeruginosa strain confers protection against acute and chronic lung infection in C57Bl/6 mice V. Fuentes Valverde* (A Coruña, Spain), P. García, M. Moscoso, M.C. Póvoa Cabral, G. Bou O0627First Plasmodium vivax malaria vaccine candidate to show in vivo efficacy against a blood-stage P. vivaxcontrolled human malaria challenge in UK adults M. Hou* (Oxford, United Kingdom), J.R. Barrett, S.E. Silk, C.M. Nielsen, A. Lias, N.J. Edwards, N. Greenwood, Y. Themistocleous, T. Rawlinson, F. Ramos Lopez, L. Kingham-Page, J.S. Cho, F.L. Nugent, A.M. Lawrie, P. Mukherjee, V.S. Chauhan, F. Martinez, M. Guilotte-Blisnick, J.M. Reimer, C.E. Chitnis, S.J. Draper, A.M. Minassian O0628Trained immunity confers long-term protection from lethal sepsis T. Roger* (Epalinges, Switzerland), E. Ciarlo, T. Heinonen, C. Theroude, M. Reverte, C. Gilbert, D. Le Roy O0629A polyclonal antibody against the OmpA-like protein BCAL2645 impairs Burkholderia cenocepacia ability to adhere and invade human epithelial cells in vitro A.M.M. Seixas* (Lisbon, Portugal), S.A. Sousa, J.R. Feliciano, S.C. Gomes, M.R. Ferreira, L.M. Moreira, J.H. Leitão O0630Real-world effectiveness of tick-borne encephalitis (TBE) vaccination: an available prevention against TBE for travelers to endemic areas S. Pugh* (New York, United States), J. Moisi, M. Kundi, I. Santonja, W. Erber, F. Angulo, L. Jodar OS15411:00 - 12:00Hall G 1-Hour Oral Session Novel combinations with potential to treat highly resistant pathogens ChairsKai Zhou (Tianjin, China) Elisabet Nielsen (Uppsala, Sweden) O0631Experimental evolution informed dose optimisation of polymyxin-rifampicin combination against multidrug-resistant Acinetobacter baumannii: a semi-mechanistic PK/PD modelling approach J. Zhao* (Melbourne, Australia), Y. Zhu, M.L. Han, H. Yu, H. Wickremasinghe, T. Velkov, Y.W. Lin, J. Li O0632Study of bacteriophage-antibiotic combinations against a MDR clinical K.pneumoniae strain A. Senhaji* (Madrid, Spain), A. Senhaji-Kacha, M. Seoane-Blanco, P. Sánchez-Soriano, M. J. Van Raaij, J. Esteban, M. García-Quintanilla O0633Assessment of flomoxef and amikacin in a hollow-fibre infection model for the potential empiric treatment of neonatal sepsis in low- and middle-income settings C. Darlow* (Liverpool, United Kingdom), N. Farrington, A. Johnson, L. Mcentee, J. Unsworth, A. Jimenez-Valverde, B. Jagota, R. Kolamunnage- Dona, R. Da Costa, S. Ellis, F. Franceschi, M.N. Neely, L.J.V. Piddock, M. Sharland, D. Shampa, W. Hope O0634Inhaled aztreonam and tobramycin dosing regimens against hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic in vitro biofilm model S.K. Breen* (Parkville, Australia), K.E. Rogers, W.L. Lee, J.R. Tait, Y. Lang, J. Zhou, J.B. Bulitta, R.L. Nation, C.B. Landersdorfer O0635In vitro synergy with colistin in combination with meropenem and avibactam against KPC-2- and OXA-48-producing Klebsiella pneumoniae with porin deficiency L. Allander* (Uppsala, Sweden), T. Söderhäll, P. Lagerbäck, L. Sandegren, T. Tängdén Monday, 25 April 2022FINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 2023111 OS15511:00 - 12:00Hall O 1-Hour Oral Session Transmission and persistence of Klebsiella spp. ChairsAlessandra Bandera (Milano, Italy) Teresa M. Coque (Madrid, Spain) O0636The plasmid-borne virulence factor aerobactin (lineageiuc3) is strongly associated with isolates ofKlebsiella pneumoniaefrom pigs and ducks. M. Gibbon* (Bath, United Kingdom), N. Couto, K. Cozens, A. Coates, D. Thiry, S. Breurec, S. Brisse, E. Feil O0637Dynamics of Klebsiella species in a high- risk hospital ward: the role of the built environment in the transmission and persistence of clones and multidrug resistant plasmids N. Guerra Pinto* (Madrid, Spain), S. Aracil-Gisbert, M.D. Fernández-De-Bobadilla, V.F. Lanza, R. Cantón, C. Soriano, G. Narváez, V. Quinteros-Fiel, M. López- Olivencia, R. De Pablo, F. Baquero, T.M. Coque O0638Clinical factors, gut microbiome and circulating host immunity in patients with colonisation and infection fromKlebsiella pneumoniae-carbapenemase (KPC)- producingKlebsiella pneumoniae D. Mangioni* (Milan, Italy), A. Facoetti, L. Lambroia, A. Liparoti, M. Rossi, M. Casana, V. Costabile, P. Bonfanti, P. Morelli, C. Alteri, B. Cassani, B. Bottazzi, A. Gori, A. Muscatello, A. Bandera O0639Gut colonisation with multidrug-resistant Klebsiella pneumoniae worsens Pseudomonas aeruginosa lung infection R. Le Guern* (Lille, France), T. Grandjean, S. Stabler, M. Bauduin, P. Gosset, E. Kipnis, R. Dessein O0640Type VI secretion system in K. pneumoniae: role in intestinal microbiota colonisation T. Merciecca* (Clermont-Ferrand, France), L. Nakusi, S. Bornes, S. Theil, O. Rendueles-Garcia, E. Cascales, C. Forestier, S. Miquel OS15611:00 - 12:00Hall D 1-Hour Case Session Management of difficult-to-treat antibiotic-resistant cases ChairRafael Canton (Madrid, Spain) O0641Compassionate use of novel nebulised reactive oxygen (RO) spray as adjunctive therapy in the management of multidrug-resistant pseudomonas infection of the parapharynx, mediastinum and pleural cavity A. Shahi* (Winchester, United Kingdom), J. Champion, E. Hammond, S. Wimbush, M. Dryden O0642Recurrent bacteraemia due to meropenem- resistantCampylobacter coli: antimicrobial profile and molecular characterisation M. Bonilla* (Barcelona, Spain), A. González-Díaz, J. Laporte-Amargos, F. Tubau, C. Gudiol, M.A. Domínguez, C. Ardanuy, M. Torrecillas O0643In vivo development of fluoroquinolone and rifamycin resistance in prolonged Elizabethkingia meningoseptica bloodstream infection A. Stewart* (Brisbane, Australia), J. Roberts, B. Forde, H. Bergh, T. Kidd, H. Wright, P. Harris O0644Multidrug-resistantKlebsiella africanaas causative pathogen of respiratory tract superinfection in a severe case of COVID-19 in Bogotá, Colombia J. Urrego* (Bogotá, Colombia), E.D. Ibáñez-Prada, C.C. Serrano-Mayorga, Y.V. Fuentes-Barreiro, I.G. Bustos-Moya, E. Gamboa-Silva, D.F. Josa- Montero, J. Hawkey, K. Wyres, A.J. Stewardson, J. Urrego-Reyes, C.C. Beltran, S. Leon, L.F. Reyes O0645Cefiderocol as a rescue treatment for nosocomial infections due to carbapenem-resistant Acinetobacter baumannii complex B. Leal De Almeida* (São Paulo, Brazil), C. Sunaitis Donini, L. Nunes De Almeida Gouveia, L. Bubach Carvalho, M. Bordignon Antonio, L. Abrahão Hajjar, J.L. Mello Sampaio, E. Georges Kallas, M.L. Do Nascimento Moura OF15711:00 - 12:00Hall K 1-Hour Mini-oral Flash Session Diagnostics in clinical and scientific parasitology ChairsSarah Delliere (Paris, France) Marjan Van Esbroeck (Antwerp, Belgium) O0646Performances of ICT toxoplasma IgG-IgM test in comparison with vidas toxo competition to determine the immune status of patients against Toxoplasma gondii H. Sandrine* (Paris, France), S. Abraham, R. Mcleod, N. Houhou-Fidouh, R. Piarroux, P. Niçaise-Rolland, L. Landraud, S. Houze O0647Cytokine production in congenital toxoplasmosis V.M.V. Meroni* (Pavia, Italy), C. Agrati, V. Bordoni, A. Vola, G. Ferrari, L. Bollani, G. Ippolito O0648Congenital toxoplasmosis: outcomes of newborns from mothers with documented seroconversion out of a multi-centre cohort in two tertiary referral hospitals A. Bonetti* (Pavia, Italy), A. Comelli, A. Chiesa, V. Spinoni, A. Vola, F. Prefumo, A. Valcamonico, C. Bonfanti, S. Caligaris, V. Meroni, L.R. Tomasoni O0649MonitoringPlasmodium falciparumgene copy numbers associated with resistance to partner drugs included in artemisinin-based combination regimens in The Gambia H. Brazal Monzó* (Murcia, Spain), H. Brazal Monzo, M. Oboh, E. Oriero, A. Ngwa O0650Accuracy of an immunochromatographic test for detection of Strongyloides stercoralis infection in migrants from sub-Saharan Africa D. Buonfrate* (Verona, Italy), F. Tamarozzi, S. Longoni, C. Mazzi, R. Noordin Monday, 25 April 2022SCIENTIFIC PROGRAMME112 O0651Elucidating the role of the skin microbiome in human attractiveness to mosquitoes A. Showering* (London, United Kingdom), J. Logan, R. Allen O0652Assessment of malaria diagnostic methods based on loop-mediated isothermal amplification assays in Spain A. Martin Ramírez* (Madrid, Spain), A. Martín Ramírez, M. Lanza Suárez, J.M. Rubio Muñoz O0653Association of HLA-B*35 and moderate or severe cutaneous reactions secondary to benznidazole treatment in chronic Chagas disease patients P. Bosch-Nicolau* (Barcelona, Spain), F. Salvador, A. Sánchez-Montalvá, C. Franco-Jarava, I. Arrese- Muñoz, E. Sulleiro, S. Roura, L. Valerio, I. Oliveira- Souto, N. Serre-Delcor, D. Pou, B. Treviño, M.L. Aznar, J. Espinosa-Pereiro, I. Molina O0654Benefits and limitations of next-generation sequencing-based metabarcoding for detection and differentiation of intestinal parasites in diagnostic, research, and One Health settings H.V. Nielsen* (Copenhagen, Denmark), C.R. Stensvold, R.P.K.D. Berg, P. Jokelainen, L.O. Andersen OF15811:00 - 12:00Hall L 1-Hour Mini-oral Flash Session Virus surveillance across different settings ChairsMichael Kann (Gothenburg, Sweden) Anna Papa-Konidari (Thessaloniki, Greece) O0655Risk of measles outbreak among children of local population posed by Afghan nomadic refugees in rural areas of Islamabad H. Ali* (Islamabad, Pakistan) O0656High-risk human papillomavirus (hrHPV) genotype-specific viral load in women with persistent infection C. Giubbi* (Monza, Italy), M. Martinelli, I. Vallini, R. Musumeci, I. Monticciolo, F. Perdoni, S. Volonté, M.L. Di Meo, R. Fruscio, F. Landoni, C.E. Cocuzza O0657Analysis of hepatic fibrosis biomarkers in serum according to the basal core promoter/precore mutations of hepatitis B virus C. Lefeuvre* (Angers, France), M. Roux, S. Blanchard, H. Le Guillou-Guillemette, J. Boursier, F. Lunel-Fabiani, P. Jeannin, A. Pivert, A. Ducancelle O0658Serological characterisation and molecular analysis of measles breakthrough cases in Milan, northern Italy (2017-2021) C. Fappani* (Milan, Italy), M. Gori, S. Bianchi, G. Ciceri, M. Dura, D. Colzani, E. Tanzi, A. Amendola O0659Adult T cell leukaemia/lymphoma in French Guiana: real-life data from 2009 to 2019 K. Abdelmoumen* (Saint-Denis, Réunion), K.D. Alsibai, F. Santa, M. Nacher, J.M. Cauvin, N.B. Wankpo, P. Naudion, C. Misslin-Tritsch, F. Djossou, A. Gessain, L. Galicier, O. Hermine, J.P. Droz, P. Couppié, L. Epelboin O0660Setting the terms for zoonotic diseases: effective communication for research, conservation, and public policy J.T. Shapiro* (Be’er Sheva, Israel), L. Víquez-R, S. Leopardi, A. Vicente-Santos, I.H. Mendenhall, W.F. Frick, R.C. Kading, R.A. Medellín, P. Racey, T. Kingston O0661Epidemiology and spectrum of predisposing conditions of progressive multifocal leukoencephalopathy: a French nationwide population-based study G. Martin-Blondel* (Bethesda, United States), M. Joly, C. Conte, C. Cazanave, V. Le Moing, P. Tattevin, P. Delobel, A. Sommet O0662Orthohepevirus C infection as an emerging cause of acute hepatitis A. Rivero-Juarez* (Cordoba, Spain), M. Frias, A.B. Perez, J.A. Pineda, G. Reina, A. Fuentes-Lopez, C. Freyre, E. Ramirez-Arellano, J.C. Alados, A. Rivero O0663Mortality in tick-borne encephalitis and other reportable zoonotic infectious diseases in Sweden R. Varnaite* (Stockholm, Sweden), S. Gredmark- Russ, J. Klingström OF15911:00 - 12:00Hall P 1-Hour Mini-oral Flash Session Predictors of disease severity and mortality in COVID-19 ChairsNathan Peiffer-Smadja (Paris, France) Willem Joost Wiersinga (Amsterdam, Netherlands) O0663ACOVID-19 treatment and outcomes in over 500,000 hospitalised patients in the United States: May 2020-June 2021 L. Chen* (Foster City, United States), A. Chandak, R.L. Gottlieb, P.E. Sax, D.A. Wohl, M. Thrun, E. Mozaffari, P. Hodgkins, R. Gupta, R. Haubrich O0664Ethnicity, migration status, country of birth, and outcomes from COVID-19 in hospitalised patients in Quebec, Canada C. Greenaway* (Montreal, Canada), A.M. Passos- Castilho, A.C. Labbé, S. Barkati, M.L. Luong, M.A. Tutt-Guérette, J. Kierans, C. Rousseau, A. Benedetti, L. Azoulay O0665Clinically relevant viremia pattern as a poor prognostic marker in COVID-19 patients: prospective study and validation cohort N.D. Zurita-Cruz* (Madrid, Spain), L. Cardeñoso- Domingo, E. Roy-Vallejo, L. Fontán-García Rodrigo, I. García Arata, E. Navarro-Lara, V.B. Valdéz-Blanco, I. González-Álvaro, R. De La Cámara, D.A. Rodríguez-Serrano O0666Predictors of survival in elderly patients with COVID-19 admitted to the hospital: an observational multi-centre study from ESGIE M. Falcone* (Pisa, Italy), G. Tiseo, I. Margalit, N. Riccardi, M. Tinelli, V. Borghi, H. Green, M. Ripa, C. Mussini, V. Prendki, A. Castagna, D. Yahav Monday, 25 April 2022FINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 2023113 O0667A single-centre retrospective observational study on the accuracy of the MuLBSTA score in predicting mortality among COVID-19 confirmed moderate to critical cases M.C.J. Poblete* (San Juan, Philippines), E.N. Adamos O0668High sera levels of SARS-CoV-2 N-antigen is associated with ICU or death in hospitalised COVID-19 patients B. Visseaux* (Paris, France), H.R. Chenane, R. Menidjel, S. Lebourgeois, C. Laouenan, S. Tubiana, D. Descamps, L. Abel, J. Guedj, S. Malhotra, S. Kumar-Singh, J. Ghosn O0669Local NETosis and systemic inflammation and complement activation predicts clinical outcome of severe SARS-CoV-2 infections R. Würzner* (Innsbruck, Austria), S. Huber, M. Massri, G. Rambach, C. Speth O0670SARS-CoV-2 nasopharyngeal viral load at admission correlates to disease severity in adults hospitalised for COVID-19 K. Hagman* (Stockholm, Sweden), M. Hedenstierna, J. Oesman, E. Arvidsson, P. Gille- Johnson, L. Grillner, J. Jakobsson, J. Ursing O0671RT-PCR CT values with age couldpredict invasive mechanical ventilation and mortality in hospitalised COVID-19 patients in a MERS-CoV- endemic country L. Akkielah* (Riyadh, Saudi Arabia), M. Barry, T. Muayqil VW16011:00 - 12:00Arena 1 Virtual Walk Through Lessons learned: will COVID-19 change IPC’s daily work? ModeratorNasia Safdar (Madison, United States) ReviewerWalter Zingg (Zurich, Switzerland) CM SY16113:30 - 15:30Hall B Symposium The role of genomics in AMR surveillance ChairsKoji Yahara (Tokyo, Japan) Nicholas Feasey (Blantyre, Malawi) S067213:30Genomics for AMR surveillance in invasive bacterial infections: add-on or a leapfrog technology? Anders Dalsgaard (Copenhagen, Denmark) S067314:00Genomic surveillance and the detection of new and emerging AMR mechanisms Senjuti Saha (Dhaka, Bangladesh) S067414:30Genomic surveillance and microevolutionary changes with new resistance development in MDR Micobacterium tuberculosis Josefina Campos (Buenos Aires, Argentina) S067515:00Genomic epidemiology reveals cross-border spread of blaOXA-48 and blaNDM-1 producing Klebsiella pneumoniae Erik Alm (Solna, Sweden) IC SY16213:30 - 14:30Hall E Symposium Year in Infection Control ChairsYehuda Carmeli (Tel Aviv, Israel) Daniel Diekema (Iowa City, United States) S067613:30Stephanie J. Dancer (Glasgow, United Kingdom) S067714:00Esther Calbo (Terrassa, Spain) ID SY16313:30 - 14:30Hall I Symposium Recent top papers in transplant ID and haem/onc ID ChairsEffrossyni Gkrania-Klotsas (Cambridge, United Kingdom) Per Ljungman (Stockholm, Sweden) S067813:30SOT-ID David Van Duin (Chapel Hill, United States) S067914:00haem/onc ID Carlota Gudiol (Barcelona, Spain) ID EW16413:30 - 15:30Hall C Educational Workshop Antifungal prophylaxis in transplantation: a benefit for which patients? ChairsPaolo Antonio Grossi (Varese, Italy) Francisco López-Medrano (Madrid, Spain) W068013:30Fungal infection in transplant patients: Where are we now? Maja Weisser Rohacek (Basel, Switzerland) W068114:00Perspectives for the improved management of invasive mould infections Johan Maertens (Leuven, Belgium) W068214:30Universal vs patient risk driven prophylaxis in lung transplant recipients Shahid Husain (Toronto, Canada) Co-organised with: ESCMID Study Group for Immunocompromised Hosts (ESGICH), International Immunocompromised Host Society (ICHS) Monday, 25 April 2022SCIENTIFIC PROGRAMME114 PH EW16513:30 - 15:30Hall F Educational Workshop Changing world of infectious diseases: urbanisation and digitalisation ChairsMaria Koliou (Nicosia, Cyprus) Maria Eugenia Gutierrez Pimentel (David, Panama) W068313:30Infectious diseases and globalised urbanisation Lone Simonsen (Roskilde, Denmark) W068414:00Implementing an innovative integrated multi- infection screening digital decision support tool (IS-MiHealth) Ana Requena-Méndez (Stockholm, Sweden) W068514:30Health Catch-UP!: digital innovations to strengthen multi-disease screening and catch- up vaccination in at-risk migrants Lucy Pollyanna Goldsmith (London, United Kingdom) Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM), ESCMID International Affairs Subcommittee (EIAS) CM EW16613:30 - 15:30Hall G Educational Workshop Antimicrobial tolerance in pathogens: bench to bedside ChairsPriscille Brodin (Lille, France) Annelies Zinkernagel (Zurich, Switzerland) W068613:30Bacterial replication and bioenergetics in antibiotic lethality and treatment-shortening activity Martin Voskuil (Aurora, United States) W068714:00Mechanisms of antimicrobial tolerance Urs Jenal (Basel, Switzerland) W068814:30Clinical implications of tolerance Jacob Strahilevitz (Jerusalem, Israel) OS16713:30 - 14:30Hall J 1-Hour Oral Session Real-life COVID-19 vaccine effectiveness ChairsSilvio Daniel Brugger (Zurich, Switzerland) Önder Ergönül (Istanbul, Turkey) O0689Epidemiology of community-acquired COVID-19 infection requiring hospitalisation in an Irish university hospital; fourth wave experience P. McGettrick* (Galway, Ireland), C. Lannon, S. Stroiescu, J. Hynes, A. Holmes, D. Gallagher, H. Tuite, B. Mcnicholas, M. Harrison, J. Sheehan, C. Fleming O0690Characteristics of SARS-CoV-2 vaccinated versus unvaccinated patients admitted to Careggi University Hospital R. Paggi* (Florence, Italy), A. Barbiero, T. Manciulli, A. Miftode, M. Tilli, F. Lagi, J. Mencarini, M. Spinicci, A. Morettini, L. Zammarchi, A. Bartoloni O0691COVID-19 cases after SARS-CoV-2 vaccination in an French university-affiliated hospital: a descriptive study C. Dananché* (Lyon, France), S. Amour, N. Romain- Scelle, C. Del Signore, A. Bal, F. Morfin, P. Vanhems O0692Impact of SARS-CoV-2 vaccination on mortality of hospitalised COVID-19 patients: a case-control study C. Cardozo* (Barcelona, Spain), R. Alonso, C. Emma, I. Armenteros, F.J. Bernal, M. De Pablo, I. Zugasti, V. Guerra, V. Rico, N. García-Pouton, M.A. Marcos, A. Soriano O0693Risk factors associated with hospitalisation and death in COVID-19 breakthrough infections G. Suleyman* (Detroit, United States), F. Fadel, I. Brar, R. Kassab, R. Khansa, N. Sturla, A. Alsaadi, K. Latack, J. Miller, R. Tibbetts, L. Samuel, G. Alangaden, M. Ramesh OS16813:30 - 14:30Hall D 1-Hour Case Session Complicated endovascular infections ChairHelen Giamarellou (Athens, Greece) O0694Mycobacterium bovisinfection of vascular grafts following BCG immunotherapy: a case report and review of literature S. Arsuffi* (Brescia, Italy), A. Cambianica, D. Ripamonti, E. Di Filippo, M. Rizzi O0695Use of dalbavancin as sequential treatment in complex cardiovascular infections: real-life experience M. Meschiari* (Modena, Italy), A. Santoro, E. Franceschini, A. Cervo, G. Orlando, A. Bedini, M. Menozzi, M. Digaetano, M. Faltoni, C. Mussini O0696Daptomycin and ceftarolin combination therapy in complicated endovascular infections caused by coagulase-negative staphylococci: a case series S. Policarpo* (Porto, Portugal), R. Duro, A. Sarmento O0697A contemporary series of Pseudomonas aeruginosa infective endocarditis A. Walczak* (Brisbane, Australia), K. Mccarthy, D. Paterson O0698An under-reported complication of vascular surgery: two cases of periprosthetic Actinomyces odontolyticus infection G. Del Fabro* (Brescia, Italy), D. Bertelli, E. Van Hauwermeiren, P. Lanza, S. Lorenzotti, B. Saccani, B. Fumarola, A. Mulè, D. Laurenda, M. Migliorati, A. Matteelli, L. Signorini Monday, 25 April 2022FINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 2023115 OF16913:30 - 14:30Hall H 1-Hour Mini-oral Flash Session Community-acquired central nervous system infections ChairsFiona McGill (Leeds, United Kingdom) Marco Oggioni (Bologna, Italy) O0699Invasive procedures and risk of brain abscess: a nationwide, population-based case control study L.H. Omland* (Copenhagen, Denmark), J. Bodilsen, J. Helweg-Larsen, J.O. Jarløv, K. Andreasen, M. Ziebell, S. Ellermann-Eriksen, U.S. Justesen, N. Frimodt-Møller, N. Obel O0700Socioeconomic functioning in patients with brain abscess: a nationwide, population-based cohort study in Denmark L.H. Omland* (Copenhagen, Denmark), J. Bodilsen, J. Helweg-Larsen, J.O. Jarløv, Z. Morten, S. Ellermann-Eriksen, U.S. Justesen, N. Frimodt- Møller, N. Obel O0701Group B streptococcus recurrent neonatal invasive infections: a retrospective study between 2008 and 2020 in France A. Tazi* (Paris, France), G. Sbaa, C. Plainvert, G. Touak, N. Dmytruk, C. Poyart O0702Seizures in adults with suspected central nervous system infection S. Olie* (Amsterdam, Netherlands), L. Ter Horst, I. Van Zeggeren, D. Van De Beek, M. Brouwer O0703Apoptosis in the hippocampus and long-term cognitive loss in experimental neurolisteriosis P. Dumez* (Bern, Switzerland), D. Grandgirard, S.L. Leib O0704Epidemiology and clinical characteristics of community-acquired meningococcal meningitis in adults T.M. Van Soest* (Amsterdam, Netherlands), N. Chekrouni, N.M. Van Sorge, M.C. Brouwer, D. Van De Beek O0705Cerebrospinal fluid neurofilament light chain concentrations predict unfavourable outcome in community-acquired bacterial meningitis N. Chekrouni* (Amsterdam, Netherlands), T. Van Soest, M. Brouwer, E. Willemse, C. Teunissen, D. Van De Beek O0706Adjuvant maraviroc exerts broad neuroprotection in acute experimental pneumococcal meningitis N.D. Le* (Bern, Switzerland), M. Steinfort, D. Grandgirard, S.L. Leib O0707Diagnosis of Lyme neuroborreliosis: what is the diagnostic value of serum Borrelia burgdorferi antibodies? M. Tetens* (Copenhagen, Denmark), R. Dessau, C. Jørgensen, J. Bodilsen, J. Møller, S. Ellermann- Eriksen, J. Bangsborg, N.S. Andersen, C. Østergaard, M. Chen, A.C. Nielsen, L.H. Omland, N. Obel, A.M. Lebech OF17013:30 - 14:30Hall K 1-Hour Mini-oral Flash Session Potential diagnostic tools for monitoring hepatotropic infections ChairsRobert Flisiak (Bialystok, Poland) Adriana Vince (Zagreb, Croatia) O0708Viral quasispecies diversity of hepatitis B among serum, oral fluid and dried blood spot samples L.M. Villar* (Rio de Janeiro, Brazil), R. Pessoa, S. Sanabani, C.S. Bezerra, M.M. Portilho, B.V. Lago O0709Hepatitis C virus fitness can influence the extent of infection-mediated epigenetic modifications in the host cells C. García-Crespo* (Madrid, Spain), I. Francisco- Recuero, I. Gallego, M. Camblor, M.E. Soria, A. López, A.I. De Ávila, A. Madejón, J. García- Samaniego, E. Domingo, A. Sánchez-Pacheco, C. Perales O0710Impact of HCV elimination in HIV infected patients on oxidative stress-related biomarkers V. Lara-Aguilar* (Majadahonda, Spain), D. Valle-Millares, M.E. Cortijo-Alfonso, C. Crespo- Bermejo, L. Martín-Carbonero, L. Domínguez, P. Ryan, I. De Los Santos, V. Briz, A. Fernández- Rodríguez O0711Identifying potential gene expression biomarkers in the peripheral blood mononuclear cells of hepatitis B related hepatocellular carcinoma: a RNA-sequencing-based study V. Poortahmasebi* (Tabriz, Iran, Islamic Republic of), A. Nejati, M. Foad Abazari, M. Nasiritoosi, A. Ghaziasadi, N. Mohammadzadeh, A. Tavakoli, A. Khamseh, N. Momenifar, O. Gholizadeh, M. Norouzi, S.M. Jazayeri O0712Evaluation of pregenomic HBV RNA for monitoring chronic hepatitis B virus infection G. Roncarati* (Bologna, Italy), S. Galli, T. Ferniani, A. Moroni, T. Lazzarotto O0713Comparison between pgRNA and HBcrAg to correctly identify the patients with HBeAg- negative chronic hepatitis B G. Roncarati* (Bologna, Italy), S. Galli, T. Ferniani, A. Moroni, T. Lazzarotto O0714The effect of treatment-induced viral eradication on cytokine and growth factor expression in chronic hepatitis C L. Radmanic* (Zagreb, Croatia), K. Bodulic, P. Simicic, A. Vince, P. Korac, S. Zidovec Lepej O0715Plasma levels of soluble markers of immune “exhaustion” sPD-1 and sTim-3 in patients with chronic hepatitis C: effect of liver fibrosis and successful treatment K. Caraballo Cortés* (Warsaw, Poland), S. Osuch, T. Laskus, M. Kruk, A. Pawelczyk, H. Berak, M. Radkowski Monday, 25 April 2022SCIENTIFIC PROGRAMME116 O0716Long-term course of liver fibrosis in HCV- monoinfected and HCV/HIV co-infected patients following direct-acting antiviral agents therapy V. Asensi* (Oviedo, Spain), L. Perez-Is, J. Collazos, B. De La Fuente, L. Morano, M. Rivas-Carmenado, M. Rodriguez, A. Romero-Favela, G.D.J. Fonseca–González, S. Melón, E. Valle-Garay PH KN17114:45 - 15:45Hall A Keynote lecture Harnessing deep learning and synthetic biology to fight pathogens Chairs Kendra Rumbaugh (Lubbock, United States) Tom Coenye (Ghent, Belgium) K071714:45 James Collins (Cambridge, United States) Jim Collins is the Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT, as well as a Member of the Harvard-MIT Health Sciences & Technology Faculty. He is also a Core Founding Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, and an Institute Member of the Broad Institute of MIT andHarvard.Heisoneofthefoundersofthefieldofsynthetic biology, and his research group is currently focused on using synthetic biology to create next-generation diagnostics and therapeutics. Prof. Collins' patented technologies have been licensed by over 25 biotech, pharma and medical device companies, and he has co-founded a number of companies, including Synlogic, Senti Biosciences, Sherlock Biosciences andCellarity,aswellasPhareBio,anon-profitfocusedonAI- driven antibiotic discovery. He has received numerous awards and honors, including a Rhodes Scholarship and a MacArthur "Genius" Award, and he is an elected member of all three national academies - the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine. Co-organised with: ESCMID Study Group for Biofilms (ESGB) Fireplace Session 25 April, 16:15 - 17:15 IC SY17214:45 - 15:45Hall E Symposium AI in infectious disease management and control ChairsCarolina Garcia-Vidal (Barcelona, Spain) Hiroshi Yotsuyanagi (Tokyo, Japan) S071814:45Machine learning for improved diagnosis of infections Melis Anahtar (Cambridge, United States) S071915:15AI for improved sepsis management Paul Elbers (Amsterdam, Netherlands) Co-organised with: Japanese Association Infectious Disease (JAID) PH SY17314:45 - 15:45Hall I Symposium Does AMR mitigation in LMICs require technical capacity more than funding? ChairsRobert Leo Skov (Copenhagen, Denmark) Ghada Zoubiane (Basel, Switzerland) S072014:45Building human technical capacity to mitigate AMR in LMICs Mirfin Mpundu (Harare, Zimbabwe) S072115:15Development funding is critical for the implementation of national action plans on AMR in LMICs Haileyesus Getahun (Geneva, Switzerland) Co-organised with: International Centre for Antimicrobial Resistance Solutions (ICARS), World Health Organization (WHO) OS17414:45 - 15:45Hall J 1-Hour Oral Session Secondary infections in COVID-19 ChairsRonen Ben-Ami (Tel Aviv, Israel) Paul Eduard Verweij (Nijmegen, Netherlands) O0723Carbapenem-resistant Enterobacterales infections in hospitalised patients with COVID-19: an Italian multi-centre observational cohort study (CREVID study) M. Falcone* (Pisa, Italy), L.R. Suardi, G. Tiseo, V. Galfo, S. Verdenelli, M. Venditti, G. Ceccarelli, S. Carbonara, M. Poli, M. Puoti, M. Merli, A. Saracino, D.F. Bavaro, T.A. Santantonio, A. Carretta, G. Nunnari, E. Venanzi Rullo, A. Cascio, C. Torti, V. Scaglione, D. Francisci, C. Papalini, A. Franco, R. Fontana Del Vecchio, R. Punzi, V. Bianco, F. Menichetti O0726COVID-19 associated aspergillosis among paediatric cancer patients R. Khedr* (Cairo, Egypt), Y. Madney, L. Shalaby, M. Hammad, M. Gaber, R. Hassan, I. Abdo, A. Zaki O0722Is COVID-19 associated pulmonary aspergillosis (CAPA) a myth? Frequency of Aspergillus detection from respiratory samples in intensive care unit patients with and without COVID-19 J. Held* (Erlangen, Germany), T. Kümmig, J. Esse, L. Herbst, R. Strauß, I. Castellanos, W. Geißdörfer, S. Mihai, N. Rakova, D. Pflaum, M. Werblow, A.K. Lang, F. Bremer, M. Ganslmayer, C. Willam Monday, 25 April 2022FINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 2023117 O0724Secondary bacterial and fungal infections among critically ill COVID-19 adult patients at a high- influx COVID-19 intensive care unit: first experiences from Hungary B.G. Szabo* (Budapest, Hungary), E. Czel, B. Lakatos, B. Petrik, I. Nagy, I. Bobek, J. Sinko O0725Digestive and oropharyngeal Enterococcus spp. and Candida spp. concentrations are associated with mortality in patients with COVID-19 in intensive care unit K. Villageois-Tran* (Clichy, France), J. Patrier, P. Szychowiak, S. Ruckly, R. Gschwind, P.H. Wicky, S. Gueye, L. Armand-Lefevre, M. Marzouk, F. Lamara, E. De Montmollin, J.F. Timsit, E. Ruppé OS17514:45 - 15:45Hall D 1-Hour Case Session Invasive fungal infections in the immunocompromised ChairMurat Akova (Ankara, Turkey) O0727Invasive fungal disease caused by Paecilomyces spp. in patients with haematological disorders Y. Rogacheva* (Saint Petersburg, Russian Federation), V. Markelov, M. Popova, A. Volkova, I. Nikolaev, O. Pinegina, S. Ignatieva, T. Bogomolova, S. Bondarenko, L. Zubarovskaya, N. Klimko, A. Kulagin O0728Microsphaeropsis arundinis: an emerging opportunistic infection in the transplant and immunocompromised patient J. Hernandez Jimenez* (Palm City, United States), M.L. Huff, L. Cardona Bonet, M. Ramgopal O0729Fungaemia caused by C. haemulonii complex and related yeasts: a series of cases in France from 2002 to 2021 U. Françoise* (Les Lilas, France), M. Desnos- Ollivier, M. Demar, K. Boukris-Sitbon, N. Desbois- Nogard, O. Lortholary O0730Chronic meningoencephalitis caused by Fusarium proliferatum: an unusual case I. Alavi Darazam* (Tehran, Iran, Islamic Republic of), G. Sharifi, E. Jamali, S. Khodavaisy, F. Javandoust Gharebagh, A. Hakamifard O0731Breakthrough invasive mould infections (bIMIs) with isavuconazole prophylaxis in patients with haematopoietic cell transplants or haematologic malignancies: a case series A. Khatri* (Miami, United States), A. Anderson, R. Jabr, J. Camargo, M. Morris, Y. Natori, M. Raja OF17614:45 - 15:45Hall K 1-Hour Mini-oral Flash Session Antibiotic stewardship in hospitals and primary care ChairsSanjay Patel (Southampton, United Kingdom) Luis Eduardo Lopez-Cortes (Seville, Spain) O0732Audit of penicillin allergy documentation and suitability for direct oral penicillin challenge to de-label patients with a non-severe penicillin allergy T. Yau* (Tooting, United Kingdom), M. Basarab, E. Clarke O0733Multisectoral antimicrobial consumption and resistance surveillance data reporting to inform antibiotic policies in human sector: the EPI-Net experience C. Mena-Benítez* (Verona, Italy), N. Babu Rajendran, F. Arieti, L. Galia, M. Tebon, M.D. Pezzani, E. Tacconelli O0734Parental antibiotic use in urban, peri-urban and rural settings in Peru: a study of knowledge, attitudes and practices J. Paredes* (Lima, Peru), R. Navarro, T.J. Ochoa O0735Use of the antibiotics according to WHO access, watch, and reserve classification in Estonian referral and central hospitals J. Lass* (Tartu, Estonia), M. Saar, K. Telling, P. Mitt, M. Maimets, I. Lutsar O0736Estimation of the overall AMR burden in Switzerland is affected by linguistic region and level of care stratifications M. Gasser* (Bern, Switzerland), A. Kronenberg O0737Association between air pollution and antimicrobial consumption in the general population of two Spanish cities: a preliminary time series analysis G. Abelenda-Alonso* (Barcelona, Spain), P. Satorra, M. Marí-Dell’olmo, C. Tebè, A. Padullès, A. Vergara, A. Rombauts, J. Carratalà O0738Carbapenem stewardship: analysis of weekly carbapenem review data M. Christie* (Durham, United Kingdom), J. Malkin O0739A cost-benefit analysis of interventions in the community to reduce the burden of antimicrobial resistance: an Irish perspective C. Halpin* (Galway, Ireland), L. Russell, M. Mcalister, R. Flynn, M. Kinahan O0740Antimicrobial resistance and migration: a qualitative study on migrants’ experiences around antibiotic use and their perceived health needs A. Al-Oraibi* (Nottingham, United Kingdom), O. Hassan, L. Silva, L. B Nellums VW17714:45 - 15:45Arena 2 Virtual Walk Through IT tools in antimicrobial stewardship ModeratorScott Bergman (Omaha, United States) ReviewerTimothy Rawson (London, United Kingdom) Monday, 25 April 2022SCIENTIFIC PROGRAMME118 ID SY17816:15 - 18:15Hall B Symposium Sepsis 2022: prevent it, spot it, treat it, beat it ChairsWillem Joost Wiersinga (Amsterdam, Netherlands) Patricia Munoz (Madrid, Spain) S074116:15Sepsis immunity, new insights from multi- omnics Luc De Chaisemartin (Châtenay-Malabry, France) S074216:45What is hot in sepsis diagnostics? Alessandra Bandera (Milano, Italy) S074317:15Long-term consequences of sepsis Manu Shankar-Hari (London, United Kingdom) S074417:45Beyond antibiotics: improving care of patients with BSI and sepsis Jordi Rello (Barcelona, Spain) Co-organised with: International Sepsis Forum (ISF), ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES) SY17916:15 - 18:15Hall E Symposium Late-breaking research from Clinical Microbiology and Infection journal ChairsAngela Huttner (Geneva, Switzerland) Andre Kalil (Omaha, United States) Details on the selected publications will be availble at a later stage CM SY18016:15 - 18:15Hall F Symposium Gut reaction: the connection between biofilms and disease ChairsJoana Azeredo (Braga, Portugal) Susanne Haeussler (Braunschweig, Germany) S074516:15Bacterial biofilms and toxins a perfect storm for colon cancer Julia Drewes (Baltimore, United States) S074616:45Bacterial biofilms in colorectal cancer initiation and progression Maikel Peppelenbosch (Rotterdam, Netherlands) S074717:15RNA landscape of emerging cancer associated microbes Joerg Vogel (Wuerzburg, Germany) S074817:45Gastrointestinal biofilms in health and disease Nathalie Vergnolle (Toulouse, France) ID SY18116:15 - 18:15Hall G Symposium Unveiling the mysteries of FMT efficacy ChairsBenoit Guery (Lausanne, Switzerland) Victoria McCune (Middlesbrough, United Kingdom) S074908:30Intestinal bile acids from faecal filtrate? Roman Melnyk (Toronto, Canada) S075009:00Which Genera of bacteria? Surbhi Malhotra-Kumar (Antwerp, Belgium) S075109:30TBA S075210:00The risk landscape of FMT Jessica Allegretti (Boston, United States) ID EW18216:15 - 18:15Hall C Educational Workshop Fungal diagnosis: questions from the bedside and answers from the bench ChairsJeremy Day (Ho Chi Minh City, Vietnam) Giuliana Lo Cascio (Piacenza, Italy) W075316:15Fungal infections, not just in neutropenia! Dimitrios P. Kontoyiannis (Houston, United States) W075416:45Role of pathogen and host pathophysiology in fungal diagnosis Cristina Cunha (Braga, Portugal) W075517:15Guidance from the bench: human and fungal markers Katrien Lagrou (Leuven, Belgium) IC EW18316:15 - 18:15Hall J Educational Workshop Prevention of nosocomial bloodstream infections ChairsSuzana Bukovski (Zagreb, Croatia) Breida Boyle (Dublin, Ireland) W075616:15Epidemiology and impact of healthcare- associated BSI Alessandro Cassini (Geneva, Switzerland) W075716:45CLABSI: successes and challenges Debby Ben-David (Holon, Israel) W075817:15Beyond the ICU: preventing nosocomial BSI hospital-wide Jean-Christophe Lucet (Paris, France) Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP) Monday, 25 April 2022FINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 2023119 OS18416:15 - 18:15Hall I 2-Hour Oral Session Microbial diversity studies across diverse settings ChairsWillem Van Schaik (Birmingham, United Kingdom) Paul Savelkoul (Maastricht, Netherlands) O0759Impacts of lumacaftor-ivacaftor on the airway mycobiota-microbiota and local inflammation are more significant in CF patients uncolonised with Pseudomonas aeruginosa F. Lussac-Sorton* (Bordeaux, France), R. Enaud, É. Charpentier, L. Velo, J. Guiraud, S. Bui, M. Fayon, T. Schaeverbeke, M. Nikolski, P.R. Burgel, G. Héry- Arnaud, L. Delhaes O0760Metagenomic analysis of gut microbiota in COVID-19 patients Y. Choi* (Lausanne, Switzerland), T. Galperine, J.L. Pagani, M. Papadimitriou, M. Méan, V. Scherz, A. Kritikos, O. Opota, G. Greub, B. Guery, C. Bertelli O076116S amplicon-based metagenomics for pathogen detection in routine diagnostic clinical microbiology S. Nassirnia* (Lausanne, Switzerland), D. Jacot, G. Greub, C. Bertelli O0762Risk of infection and death and gut microbiota composition in patients with advanced liver disease E. Rubio Garcia* (Barcelona, Spain), B.I. Fidalgo, A. Sellares, F. Aziz, M. Hernandez, J. Fernandez, J. Vila, A. Soriano, A. Vergara, C. Casals-Pascual O0763Microbiome analysis and seminal fluid detection on underwear as promising and robust sexual assault evidence S. Ahannach* (Antwerp, Belgium), I. Spacova, T. Gehrmann, S. Wittouck, J. Hiers, R. Decorte, E. Jehaes, S. Lebeer O0764Impact ofceftibuten, ciprofloxacin, co- trimoxazole,nitrofurantoin and pivmecillinamon the intestinal microbiota: a randomised controlled trial withhealthy adults H. Montelin* (Uppsala, Sweden), J.W. Debelius, A. Nääs, J.D. Järhult, C. Giske, L. Engstrand, T. Tängdén O0765Specific gut microbiome and serum metabolome changes in lung cancer patients X. Wang* (Hangzhou, China), F. Zhao, R. An, J. Shan O0766Microbiota dysbiosis clustered by Pseudomonas aeruginosa load in bronchiectasis patients R. Lopez-Aladid* (Barcelona, Spain), L. Fernández- Barat, L. Bueno-Freire, N. Vázquez, R. Pastor- Ibañez, V. Alcaraz-Serrano, A. Palomeque, R. Amaro, P. Oscanoa, A. Torres O0767Alteration of gut microbiota diversity after allogeneic haematopoietic stem cell transplantation: a pilot study K. Jutivorakool* (Bangkok, Thailand), T. Chatsuwan O0768Effect of tebipenem on the normal gut microbiota of healthy adult population T. Wondimu* (Stockholm, Sweden), T. Sewunet, M. Razzavi, A. Camporeale, S. Rosenborg, M. Nowak, D. Melnick, L.B. Gasink, P.B. Eckburg, I.A. Critchley, C.E. Nord, C.G. Giske OS18516:15 - 17:15Hall D 1-Hour Case Session Uncommon systemic infections ChairAdrian John Brink (Cape Town, South Africa) O0768AThe first reported case of human infection with Variovorax durovernum; a novel species of Variovorax spp. isolated from a prosthetic aortic graft of a shepherd L. Payne* (London, United Kingdom), A. Alcolea- Medina, L.B. Snell, C. Alder, T. Charalampous, J.D. Edgeworth, R. Batra, J.L. Klein, A.L. Goodman O0769Detection of invasive Bartonella infections with next-generation sequencing of microbial cell- free DNA F. Centeno* (Houston, United States), A. Hamdi, M. Al Mohajer O0770A fatal case of disseminated nocardiosis due to Nocardia otitidiscaviarumresistant to trimethoprim-sulfamethoxazole S. Alshehri* (Riyadh, Saudi Arabia), M. Barry, A. Ahlam, M. Barry, A. Alhijji, K. Binkhamis, F. Al-Shahrani, A. Alsharidi, M. Taim O0771Renal actinomycosis: a frequently overlooked disease with serious risks M. Romdhani* (Tunis, Tunisia), S. Hannachi, R. Abid, R. Battikh O0772A case of Wohlfahrtiimonas chitiniclastica bacteraemia in Spain Y. García Collado* (Malaga, Spain), C. García Pérez, R. Martínez Pérez, E. Clavijo Frutos, M.V. García López VW18616:15 - 17:15Arena 2 Virtual Walk Through AMR from wastewater and aquatic environment ModeratorMonika Dolejska (Brno, Czech Republic) ReviewerHillary Craddock (Be'er Sheva, Israel) Monday, 25 April 2022Next >